Literature DB >> 23747601

Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.

Yasuo Morishima1, Takakazu Kawase, Mari Malkki, Satoko Morishima, Stephen Spellman, Koichi Kashiwase, Shunichi Kato, Anne Cesbron, Jean-Marie Tiercy, David Senitzer, Andrea Velardi, Effie W Petersdorf.   

Abstract

The significance of patient and donor ethnicity on risk of acute graft-versus-host disease (GVHD) and disease relapse after unrelated donor hematopoietic cell transplantation (HCT) is not known. A total of 4335 patient-donor pairs from the International Histocompatibility Working Group in HCT met the following 3 criteria: (1) HLA-A, -B, -C, -DRB1, and -DQB1 allele matched donor, (2) diagnosis of leukemia, and (3) non-T cell depleted GVHD prophylaxis. Posttransplantation risks of acute GVHD and leukemia relapse were defined in Asian/Pacific Islander, white, African American, Hispanic, and Native American patients that underwent transplantation from donors with the same self-described background. Asian patients had a significantly lower incidence of acute GVHD (Japanese patients: 40.0% grades II to IV and 15.3% grades III to IV; non-Japanese Asian patients: 42.1% grades II to IV and 15.7% grades III to IV) compared with white patients (56.5% grades II to IV and 22.6% grades III to IV) (P < .001). The hazard ratio of acute GVHD for white patients was significantly higher than for Japanese patients. Unexpectedly, the hazard ratio of leukemia relapse in white patients with early disease status was also significantly higher than that in Japanese patients. These results provide a platform for future investigation into the genetic factors for unrelated donor HCT and clinical implications of diverse ethnic background.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute Graft-versus-host disease; Ethnicity; Leukemia relapse; Unrelated donor transplantation

Mesh:

Substances:

Year:  2013        PMID: 23747601      PMCID: PMC3972059          DOI: 10.1016/j.bbmt.2013.05.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

Review 1.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.

Authors:  E Goulmy
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

Review 2.  Immunogenomics of unrelated hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2006-07-25       Impact factor: 7.486

3.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Authors:  Yasuo Morishima; Takehiko Sasazuki; Hidetoshi Inoko; Takeo Juji; Tatsuya Akaza; Ken Yamamoto; Yoshihide Ishikawa; Shunichi Kato; Hiroshi Sao; Hisashi Sakamaki; Keisei Kawa; Nobuyuki Hamajima; Shigetaka Asano; Yoshihisa Kodera
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Effects of race on survival after stem cell transplantation.

Authors:  Marco Mielcarek; Theodore Gooley; Paul J Martin; Thomas R Chauncey; Bessie A Young; Rainer Storb; Beverly Torok-Storb
Journal:  Biol Blood Marrow Transplant       Date:  2005-03       Impact factor: 5.742

5.  Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.

Authors:  Hakumei Oh; Fausto R Loberiza; Mei-jie Zhang; Olle Ringdén; Hideki Akiyama; Takayoshi Asai; Shuichi Miyawaki; Shinichiro Okamoto; Mary M Horowitz; Joseph H Antin; Asad Bashey; Jennifer M Bird; Matthew H Carabasi; Joseph W Fay; Robert Peter Gale; Roger H Giller; John M Goldman; Gregory A Hale; Richard E Harris; Jean Henslee-Downey; Hans-Jochem Kolb; Mark R Litzow; Philip L McCarthy; Steven M Neudorf; Derek S Serna; Gerard Socié; Pierre Tiberghien; A John Barrett
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

6.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

7.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

Authors:  E W Petersdorf; T A Gooley; C Anasetti; P J Martin; A G Smith; E M Mickelson; A E Woolfrey; J A Hansen
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

9.  14thInternational HLA and Immunogenetics Workshop: report on hematopoietic cell transplantation.

Authors:  E Petersdorf; P Bardy; A Cambon-Thomsen; E Goulmy; J Hansen; A Schwarer; A Velardi
Journal:  Tissue Antigens       Date:  2007-04

10.  MHC haplotype matching for unrelated hematopoietic cell transplantation.

Authors:  Effie W Petersdorf; Mari Malkki; Ted A Gooley; Paul J Martin; Zhen Guo
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

View more
  26 in total

1.  A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.

Authors:  S Fuji; S W Kim; S Yano; S Hagiwara; H Nakamae; M Hidaka; T Ito; K Ohashi; K Hatanaka; A Takami; S Kurosawa; T Yamashita; T Yamaguchi; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

2.  Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Authors:  Olle Ringdén; Mats Remberger; Johan Törlén; Sigrun Finnbogadottir; Britt-Marie Svahn; Behnam Sadeghi
Journal:  Int J Hematol       Date:  2021-02-05       Impact factor: 2.490

3.  Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.

Authors:  K Kawamura; J Kanda; S Fuji; M Murata; K Ikegame; K Yoshioka; T Fukuda; Y Ozawa; N Uchida; K Iwato; T Sakura; M Hidaka; H Hashimoto; T Ichinohe; Y Atsuta; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

4.  Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Osamu Imataki; Kensuke Matsumoto; Makiko Uemura
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-06       Impact factor: 4.553

5.  Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL.

Authors:  J Harvey; A Green; S J Groves; J Cornish; J Moppett; M Cummins; L Keen; S Culliford; A Poles; W Hulme; Y Li; C G Steward
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

6.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

7.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

8.  Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.

Authors:  Takahiko Nakane; Hirohisa Nakamae; Takuhiro Yamaguchi; Saiko Kurosawa; Atsuo Okamura; Michihiro Hidaka; Shigeo Fuji; Akio Kohno; Takeshi Saito; Yasutaka Aoyama; Kazuo Hatanaka; Yoshio Katayama; Kimikazu Yakushijin; Toshimitsu Matsui; Motohiro Yamamori; Akiyoshi Takami; Masayuki Hino; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2016-12-09       Impact factor: 2.490

9.  Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.

Authors:  S H Shin; Y W Jeon; J H Yoon; S A Yahng; S E Lee; B S Cho; K S Eom; Y J Kim; S Lee; C K Min; H J Kim; S G Cho; D W Kim; W S Min; J W Lee
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

10.  Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.

Authors:  K Yakushijin; Y Atsuta; N Doki; A Yokota; H Kanamori; T Miyamoto; C Ohwada; K Miyamura; Y Nawa; M Kurokawa; I Mizuno; T Mori; M Onizuka; J Taguchi; T Ichinohe; H Yabe; Y Morishima; K Kato; R Suzuki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.